Diabetic dyslipidemia: Beyond LDL;Diabetische Dyslipoproteinämie: Jenseits von LDL

Deutsche Medizinische Wochenschrift

Volumn 134, Issue 20, 2009, Pages 1067-1073

  Merkel, M ^a  

^a DEPARTMENT OF CARDIOLOGY   (Germany)

Author keywords

Diabetes; Dyslipidemia; HDL; Remnants; Small dense LDL; Therapy; Triglyzerides

Indexed keywords

ADIPOCYTOKINE; ANGIOPOIETIN LIKE 3 PROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; BEZAFIBRATE; C REACTIVE PROTEIN; CERIVASTATIN; CHOLESTEROL; CHYLOMICRON REMNANT; EZETIMIBE; FENOFIBRATE; GEMFIBROZIL; GLUCOKINASE RECEPTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1; INTERLEUKIN 6; LAROPIPRANT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINE DERIVATIVE; PACTIMIBE; PHOSPHOLIPID; PROTEIN; TORCETRAPIB; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; ANTILIPEMIC AGENT; CLOFIBRIC ACID; NICOTINIC ACID; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTERIOSCLEROSIS; ATHEROGENESIS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIAGNOSTIC TEST; DIET; DYSLIPIDEMIA; DYSLIPOPROTEINEMIA; HEART INFARCTION; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LABORATORY TEST; LIPID HYDROLYSIS; LIPOPROTEIN BLOOD LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOGENESIS; PHOSPHOLIPID BLOOD LEVEL; POSTPRANDIAL STATE; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION; ATHEROSCLEROSIS; BLOOD; LOW FAT DIET; METABOLISM;

ANTILIPEMIC AGENTS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CHOLESTEROL, VLDL; CHYLOMICRON REMNANTS; CLOFIBRIC ACID; DIABETES MELLITUS, TYPE 2; DIET, FAT-RESTRICTED; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NIACIN; TRIGLYCERIDES; WEIGHT LOSS;

EID: 65649090664     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0029-1222571     Document Type: Review

References (54)

1. American Diabetes Association. Standards of Medical Care in Diabetes - 2008. Diabetes Care 2008; 31: S12-S54.
2. Assmann G, Schulte H, Seedorf U. Cardiovascular risk assessment in the metabolic syndrome: results from the Prospective Cardiovascular Munster (PROCAM) Study. Int J Obes (Lond) 2008; 32 SUPPL. 2: S11-6
3. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990; 82: 495-506
4. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. Jama 2007; 298: 309-16
5. Barter PJ, Caulfield M, Eriksson M et al Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357: 2109-22
6. Belsey J, de Lusignan S, van Vlymen J, Chan T, Hague N. Reducing coronary risk by raising HDL-cholesterol: risk modelling the addition of nicotinic acid to existing therapy. Curr Med Res Opin 2008; 24: 2703-9
7. Bloedon LT, Dunbar R, Duffy D et al. Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J Lipid Res 2008; 49: 1344-52
8. Conner PL, Berge KG, Wenger NK et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986; 8: 1245-55.
9. Carlson L, Böttiger L. Ischaemic heart-disease in relation to fasting values of plasma triglycerides and cholesterol. Stockholm prospective study. Lancet 1972; 1: 865-8
10. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000; 102: 1082-5 (Pubitemid 30672833)
11. Das A, Davis MA Tomoda H, Omura S, Rudel LL Identification of the interaction site within acyl-CoA:cholesterol acyltransferase 2 for the isoform- specific inhibitor pyripyropene A.J Biol Chem 2008; 283:10453-60.
12. Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: A meta-analysis. Am J Clin Nutr 1992; 56: 320-8.
13. Frick MH, Elo O, Haapa K et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237-45
14. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
15. Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. Jama 1996; 276: 875-81
16. Ginsberg HN. Lipoprotein physiology in nondiabetic and diabetic states. Relationship to atherogenesis. Diabetes Care 1991; 14: 839-55
17. Ginsberg HN, Zhang YL, Hernandez-Ono A. Regulation of plasma triglycerides in insulin resistance and diabetes. Arch Med Res 2005; 36: 232-40.
18. Goldenberg I, Benderly M, Goldbourt U. Secondary prevention with bezafibrate therapy for the treatment of dyslipidemia: An extended follow-up of the BIP trial. J Am Coll Cardiol 2008; 51: 459-65
19. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977; 62: 707-14
20. Grundy SM. Promise of low-density lipoprotein-lowering therapy for primary and secondary prevention. Circulation 2008; 117: 569-73.
21. Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-39
22. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: A meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3: 213-9
23. Horowitz BS, Goldberg IJ, Merab J, Vanni TM, Ramakrishnan R, Ginsberg HN. Increased plasma and renal clearance of an exchangeable pool of apolipoprotein A-I in subjects with low levels of high density lipoprotein cholesterol.J Clin Invest 1993; 91: 1743-52
24. Karpe F, Bickerton AS, Hodson L, Fielding BA, Tan GD, Frayn KN. Removal of triacylglycerols from chylomicrons and VLDL by capillary beds: the basis of lipoprotein remnant formation. Biochem Soc Trans 2007;35:472-6
25. Kearney PM, Blackwell L, Collins R et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: A meta-analysis. Lancet 2008; 371: 117-25
26. Keech A, Simes RJ, Barter P et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-61
27. Kluger M, Heeren J, Merkel M. Apoprotein A-V: An important regulator of triglyceride metabolism. J Inherit Metab Dis 2008; 31: 281- 288
28. Kraus WE, Houmard JA, Duscha BD et al. Effects of the amount and intensity of exercise on plasma lipoproteins. N Engl J Med 2002; 347: 1483-92.
29. Lahdenpera S, Syvanne M, Kahri J, Taskinen MR. Regulation of low-density lipoprotein particle size distribution in NIDDM and coronary disease: importance of serum triglycerides. Diabetologia 1996; 39: 453-61
30. Lamarche B, Tchernof A, Moorjani S et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation 1997; 95: 69-75 (Pubitemid 27029945)
31. Levy Y. High-density lipoprotein mass, cholesteryl ester transport protein, and macrophage reverse cholesterol transport: from the bedside back to the bench. Cardiovasc Res 2008; 77: 614-5
32. McKenney JM, Jones PH, Adamczyk MA, Cain VA, Bryzinski BS, Blasetto JW. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin 2003; 19: 689-98
33. McNamara JR, Shah PK, Nakajima K et al. Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham Heart Study. Atherosclerosis 2001;154:229-36
34. Merkel M, Eckel RH, Goldberg IJ. Lipoprotein lipase: genetics, lipid uptake and regulation. J Lipid Res 2002; 43: 1997-2006.
35. Muller-Wieland D, Kotzka J. SREBP-1: gene regulatory key to syndrome X? Ann N Y Acad Sci 2002; 967: 19-27.
36. National Cholesterol Education Program (NCEP). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421.
37. Nissen SE, Tsunoda T, Tuzcu EM et al. Effect of recombinant ApoA-I Mila- no on coronary atherosclerosis in patients with acute coronary syndromes: A randomized controlled trial. JAMA 2003; 290: 2292-300
38. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007; 298: 299-308.
39. Otvos JD, Collins D, Freedman DS et al. Low-density lipoprotein and high- density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High- Density Lipoprotein Intervention Trial. Circulation 2006; 113: 1556-63
40. Parhofer KG, Laubach E, Geiss HC, Otto C. Einfluss einer verbesserten Blutzuckereinstellung auf den Lipidspiegel bei Patienten mit Typ-2- Diabetes. Dtsch Med Wochenschr 2002; 127: 958-62.
41. Ridker PM. Cardiology Patient Page. C-reactive protein: A simple test to help predict risk of heart attack and stroke. Circulation 2003; 108: e81-5.
42. Rubins HB, Robins SJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high- density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341:410-8
43. Ryden L, Standi E, Bartnik M et al. Guidelines on diabetes, prediabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28: 88-136
44. Saha SA, Kizhakepunnur LG, Bahekar A, Arora RR. The role of fibrates in the prevention of cardiovascular disease - a pooled meta-analysis of long-term randomized placebo-controlled clinical trials. Am Heart J 2007; 154: 943-53
45. Samaha EE, McKenney J, Bloedon LT, Sasiela WJ, Rader DJ. Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nat Clin Pract Cardiovasc Med 2008; 5: 497-505
46. SarwarN, Danesh J, Eiriksdottir G et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007; 115: 450-8
47. Schramm TK, Gislason GH, Kober L et al. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: A population study of 3.3 million people. Circulation 2008; 117: 1945-54
48. Smith SC Jr, Allen J, Blair SN et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006; 113: 2363-72 (Pubitemid 43947981)
49. Van Acker BA, Botma GJ, Zwinderman AH et al. High HDL cholesterol does not protect against coronary artery disease when associated with combined cholesteryl ester transfer protein and hepatic lipase gene variants. Atherosclerosis 2008; 200: 161-7
50. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): A prospective study. Lancet 2001; 358: 2026-33
51. Wang J, Ban MR, Zou GY et al. Polygenic determinants of severe hypertriglyceridemia. Hum Mol Genet 2008; 17: 2894-9
52. Yusuf S, Hawken S, Ounpuu S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937-52
53. Zambon A, Bertocco S, Vitturi N, Polentarutti V, Vianello D, Crepaldi G. Relevance of hepatic lipase to the metabolism of triacylglycerol-rich lipoproteins. Biochem Soc Trans 2003; 31: 1070-4
54. Zilversmit DB. Atherogenesis: A postprandial phenomenon. Circulation 1979;60:473-85